WallStreetZenWallStreetZen

NASDAQ: OLMA
Olema Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for OLMA

Based on 5 analysts offering 12 month price targets for Olema Pharmaceuticals Inc

Min Forecast
$18.00+226.68%
Avg Forecast
$24.00+335.57%
Max Forecast
$30.00+444.46%

Should I buy or sell OLMA stock?

Based on 5 analysts offering ratings for Olema Pharmaceuticals Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although OLMA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates OLMA as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their OLMA stock forecasts and price targets.

OLMA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-14
lockedlocked$00.00+00.00%2025-08-12Find Out Why
lockedlocked$00.00+00.00%2025-05-14
lockedlocked$00.00+00.00%2025-05-14
lockedlocked$00.00+00.00%2025-04-28

1 of 1

Forecast return on equity

Is OLMA forecast to generate an efficient return?

Company
-28.23%
Industry
125.25%
Market
-47.51%
OLMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OLMA forecast to generate an efficient return on assets?

Company
-25.51%
Industry
47.65%
OLMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OLMA earnings per share forecast

What is OLMA's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.74
Avg 2 year Forecast
-$2.30
Avg 3 year Forecast
-$1.96

OLMA revenue forecast

What is OLMA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$22.5M
Avg 2 year Forecast
$36.5M
Avg 3 year Forecast
$78.8M

OLMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OLMA$5.51$24.00+335.57%Strong Buy
XOMA$31.37$69.50+121.55%Strong Buy
NBTX$7.91$8.00+1.14%Strong Buy
YMAB$8.52$10.87+27.55%Hold
ATXS$6.85$32.80+378.83%Strong Buy
View Top Biotech Stocks

Olema Pharmaceuticals Stock Forecast FAQ

Is Olema Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: OLMA) stock is to Strong Buy OLMA stock.

Out of 5 analysts, 3 (60%) are recommending OLMA as a Strong Buy, 2 (40%) are recommending OLMA as a Buy, 0 (0%) are recommending OLMA as a Hold, 0 (0%) are recommending OLMA as a Sell, and 0 (0%) are recommending OLMA as a Strong Sell.

If you're new to stock investing, here's how to buy Olema Pharmaceuticals stock.

What is OLMA's earnings growth forecast for 2025-2027?

(NASDAQ: OLMA) Olema Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Olema Pharmaceuticals's earnings in 2025 is -$142,295,000.On average, 5 Wall Street analysts forecast OLMA's earnings for 2025 to be -$119,149,195, with the lowest OLMA earnings forecast at -$133,836,942, and the highest OLMA earnings forecast at -$107,069,553. On average, 5 Wall Street analysts forecast OLMA's earnings for 2026 to be -$157,858,957, with the lowest OLMA earnings forecast at -$264,928,510, and the highest OLMA earnings forecast at -$94,029,031.

In 2027, OLMA is forecast to generate -$134,180,113 in earnings, with the lowest earnings forecast at -$142,759,404 and the highest earnings forecast at -$125,600,822.

What is OLMA's revenue growth forecast for 2026-2028?

(NASDAQ: OLMA) Olema Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.

Olema Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast OLMA's revenue for 2026 to be $1,544,272,403, with the lowest OLMA revenue forecast at $1,544,272,403, and the highest OLMA revenue forecast at $1,544,272,403. On average, 2 Wall Street analysts forecast OLMA's revenue for 2027 to be $2,504,123,494, with the lowest OLMA revenue forecast at $1,708,994,792, and the highest OLMA revenue forecast at $3,299,252,195.

In 2028, OLMA is forecast to generate $5,408,385,125 in revenue, with the lowest revenue forecast at $5,408,385,125 and the highest revenue forecast at $5,408,385,125.

What is OLMA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: OLMA) forecast ROA is -25.51%, which is lower than the forecast US Biotechnology industry average of 47.65%.

What is OLMA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year OLMA price target, the average OLMA price target is $24.00, with the highest OLMA stock price forecast at $30.00 and the lowest OLMA stock price forecast at $18.00.

On average, Wall Street analysts predict that Olema Pharmaceuticals's share price could reach $24.00 by Aug 14, 2026. The average Olema Pharmaceuticals stock price prediction forecasts a potential upside of 335.57% from the current OLMA share price of $5.51.

What is OLMA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: OLMA) Olema Pharmaceuticals's current Earnings Per Share (EPS) is -$1.87. On average, analysts forecast that OLMA's EPS will be -$1.74 for 2025, with the lowest EPS forecast at -$1.95, and the highest EPS forecast at -$1.56. On average, analysts forecast that OLMA's EPS will be -$2.30 for 2026, with the lowest EPS forecast at -$3.86, and the highest EPS forecast at -$1.37. In 2027, OLMA's EPS is forecast to hit -$1.96 (min: -$2.08, max: -$1.83).

What is OLMA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: OLMA) forecast ROE is -28.23%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.